• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Concentra Group Holdings Parent Inc.

    12/9/24 6:02:26 AM ET
    $CON
    Medical Specialities
    Health Care
    Get the next $CON alert in real time by email
    SC 13G 1 con13gnov24.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) CONCENTRA GROUP HOLDINGS PAR (Name of Issuer) COMMON STOCK (Title of Class of Securities) 20603L102 (CUSIP NUMBER) November 30, 2024 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 17,709,382 6. Shared Voting Power* 0 7. Sole Dispositive Power* 17,770,513 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 17,770,513 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 14.0% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: CONCENTRA GROUP HOLDINGS PAR Item 1(b) Address of Issuer's Principal Executive Offices: C/O SELECT MEDICAL CORPORATION, 4714 GETTYSBURG RD., P.O. BOX 2034, MECHANICSBURG, PA 17055 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. (Price Associates) Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 20603L102 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class Not Applicable Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) [T. ROWE PRICE MID-CAP VALUE FUND ]: T. ROWE PRICE MID-CAP VALUE FUND, of which T. ROWE PRICE ASSOCIATES, INC. is the investment adviser, holds the securities reported herein in their investment portfolio managed by T. ROWE PRICE ASSOCIATES, INC. and such funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities that they hold. T. ROWE PRICE MID-CAP VALUE FUND has an interest in 9,661,924 of the class reported herein representing 7.6% of the class. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: December 6, 2024 Signature: /s/ Ellen York Name & Title: Ellen York, Vice President 11/30/2024
    Get the next $CON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CON

    DatePrice TargetRatingAnalyst
    12/16/2024$24.00Neutral → Buy
    BofA Securities
    10/7/2024$30.50 → $24.00Buy → Neutral
    BofA Securities
    8/20/2024$33.00Outperform
    RBC Capital Mkts
    8/19/2024Buy
    BofA Securities
    8/19/2024$29.00Buy
    Deutsche Bank
    8/19/2024$29.00Overweight
    JP Morgan
    8/19/2024$32.00Buy
    Goldman
    8/19/2024$28.00Outperform
    Mizuho
    More analyst ratings

    $CON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Concentra Group Holdings Parent upgraded by BofA Securities with a new price target

      BofA Securities upgraded Concentra Group Holdings Parent from Neutral to Buy and set a new price target of $24.00

      12/16/24 6:50:31 AM ET
      $CON
      Medical Specialities
      Health Care
    • Concentra Group Holdings Parent downgraded by BofA Securities with a new price target

      BofA Securities downgraded Concentra Group Holdings Parent from Buy to Neutral and set a new price target of $24.00 from $30.50 previously

      10/7/24 7:46:54 AM ET
      $CON
      Medical Specialities
      Health Care
    • RBC Capital Mkts initiated coverage on Concentra Group Holdings Parent with a new price target

      RBC Capital Mkts initiated coverage of Concentra Group Holdings Parent with a rating of Outperform and set a new price target of $33.00

      8/20/24 6:52:13 AM ET
      $CON
      Medical Specialities
      Health Care

    $CON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Concentra Group Holdings Parent, Inc. Announces Results For Its First Quarter Ended March 31, 2025, Cash Dividend, and Revised FY 2025 Guidance

      Concentra Group Holdings Parent, Inc. ("Concentra," the "Company," "we," "us," or "our") (NYSE:CON), the nation's largest provider of occupational health services, today announced results for its first quarter ended March 31, 2025, and the declaration of a cash dividend. "Concentra reported a solid start to 2025 with strong revenue and Adjusted EBITDA growth in the first quarter. With a deep understanding of patient and client needs and market dynamics, we continue to execute on key drivers of growth and deliver a comparative market advantage. Maintaining this focus ensures we continue to achieve our strategic business objectives for the year," said Keith Newton, Chief Executive Officer of

      5/7/25 4:30:00 PM ET
      $CON
      Medical Specialities
      Health Care
    • Concentra® Announces Signing of Definitive Agreement to Acquire Pivot Onsite Innovations

      Concentra Group Holdings Parent, Inc. ("Concentra," "the Company," "we," "us," or "our") (NYSE:CON), the nation's largest provider of occupational health services, today announced the signing of a definitive agreement to acquire Pivot Onsite Innovations from Athletico Physical Therapy. Pivot Onsite Innovations is a leader in the onsite health industry with over 200 onsite health clinics at employer locations in over 40 states. "Joining forces with Pivot Onsite Innovations represents an exciting new chapter for Concentra Onsite Health," said Matt DiCanio, Concentra's President and Chief Financial Officer. "Since 1993, our onsite health clinics have provided employees with immediate access t

      4/21/25 9:00:00 AM ET
      $CON
      Medical Specialities
      Health Care
    • Concentra® to Announce First Quarter 2025 Results on Wednesday, May 7, 2025

      Concentra® Group Holdings Parent, Inc. ("Concentra") (NYSE:CON) will release the financial results for its first quarter ended March 31, 2025, on Wednesday, May 7, 2025, after the market closes. Concentra will host a conference call regarding its financial results on Thursday, May 8, 2025, at 9 a.m. Eastern Time. The conference call will be a live webcast and can be accessed via this Earnings Call Webcast Link or via Concentra's website at https://ir.concentra.com. A replay of the webcast will be available shortly after the call at the same locations. Participants may join the audio-only version of the webcast or participate in the question-and-answer session by calling: Toll Free: 888-5

      4/7/25 4:30:00 PM ET
      $CON
      Medical Specialities
      Health Care

    $CON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ortenzio Robert A disposed of 3,070,367 shares and acquired 1,023,455 shares (SEC Form 4)

      4 - Concentra Group Holdings Parent, Inc. (0002014596) (Issuer)

      3/4/25 4:59:26 PM ET
      $CON
      Medical Specialities
      Health Care
    • Officer Mcandrew Douglas R. was granted 60,000 shares (SEC Form 4)

      4 - Concentra Group Holdings Parent, Inc. (0002014596) (Issuer)

      11/29/24 5:59:48 PM ET
      $CON
      Medical Specialities
      Health Care
    • Officer Kosuth Michael A. was granted 60,000 shares (SEC Form 4)

      4 - Concentra Group Holdings Parent, Inc. (0002014596) (Issuer)

      11/29/24 5:58:45 PM ET
      $CON
      Medical Specialities
      Health Care

    $CON
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Concentra Group Holdings Parent Inc.

      SCHEDULE 13G/A - Concentra Group Holdings Parent, Inc. (0002014596) (Subject)

      5/14/25 10:45:26 AM ET
      $CON
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Concentra Group Holdings Parent Inc.

      10-Q - Concentra Group Holdings Parent, Inc. (0002014596) (Filer)

      5/7/25 4:49:01 PM ET
      $CON
      Medical Specialities
      Health Care
    • Concentra Group Holdings Parent Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Concentra Group Holdings Parent, Inc. (0002014596) (Filer)

      5/7/25 4:36:13 PM ET
      $CON
      Medical Specialities
      Health Care

    $CON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Concentra Group Holdings Parent Inc.

      SC 13G - Concentra Group Holdings Parent, Inc. (0002014596) (Subject)

      12/9/24 6:02:26 AM ET
      $CON
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Concentra Group Holdings Parent Inc.

      SC 13G - Concentra Group Holdings Parent, Inc. (0002014596) (Subject)

      12/6/24 4:32:57 PM ET
      $CON
      Medical Specialities
      Health Care
    • SEC Form SC 13D filed by Concentra Group Holdings Parent Inc.

      SC 13D - Concentra Group Holdings Parent, Inc. (0002014596) (Subject)

      12/3/24 4:21:17 PM ET
      $CON
      Medical Specialities
      Health Care

    $CON
    Leadership Updates

    Live Leadership Updates

    See more
    • Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600

      NEW YORK, Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE:ENV) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 25. Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions. Azenta's market capitalization is no longer representative of the mid-cap market space.Concentra Group Holdings Inc. (NYSE:CON) will replace Myers Industries Inc. (NYSE:MYE) in the S&P SmallCap 600 effective prior to the openin

      11/19/24 5:56:00 PM ET
      $AZTA
      $CON
      $ENV
      $FLEX
      Industrial Machinery/Components
      Technology
      Medical Specialities
      Health Care

    $CON
    Financials

    Live finance-specific insights

    See more
    • Concentra Group Holdings Parent, Inc. Announces Results For Its First Quarter Ended March 31, 2025, Cash Dividend, and Revised FY 2025 Guidance

      Concentra Group Holdings Parent, Inc. ("Concentra," the "Company," "we," "us," or "our") (NYSE:CON), the nation's largest provider of occupational health services, today announced results for its first quarter ended March 31, 2025, and the declaration of a cash dividend. "Concentra reported a solid start to 2025 with strong revenue and Adjusted EBITDA growth in the first quarter. With a deep understanding of patient and client needs and market dynamics, we continue to execute on key drivers of growth and deliver a comparative market advantage. Maintaining this focus ensures we continue to achieve our strategic business objectives for the year," said Keith Newton, Chief Executive Officer of

      5/7/25 4:30:00 PM ET
      $CON
      Medical Specialities
      Health Care
    • Concentra® Announces Signing of Definitive Agreement to Acquire Pivot Onsite Innovations

      Concentra Group Holdings Parent, Inc. ("Concentra," "the Company," "we," "us," or "our") (NYSE:CON), the nation's largest provider of occupational health services, today announced the signing of a definitive agreement to acquire Pivot Onsite Innovations from Athletico Physical Therapy. Pivot Onsite Innovations is a leader in the onsite health industry with over 200 onsite health clinics at employer locations in over 40 states. "Joining forces with Pivot Onsite Innovations represents an exciting new chapter for Concentra Onsite Health," said Matt DiCanio, Concentra's President and Chief Financial Officer. "Since 1993, our onsite health clinics have provided employees with immediate access t

      4/21/25 9:00:00 AM ET
      $CON
      Medical Specialities
      Health Care
    • Concentra® to Announce First Quarter 2025 Results on Wednesday, May 7, 2025

      Concentra® Group Holdings Parent, Inc. ("Concentra") (NYSE:CON) will release the financial results for its first quarter ended March 31, 2025, on Wednesday, May 7, 2025, after the market closes. Concentra will host a conference call regarding its financial results on Thursday, May 8, 2025, at 9 a.m. Eastern Time. The conference call will be a live webcast and can be accessed via this Earnings Call Webcast Link or via Concentra's website at https://ir.concentra.com. A replay of the webcast will be available shortly after the call at the same locations. Participants may join the audio-only version of the webcast or participate in the question-and-answer session by calling: Toll Free: 888-5

      4/7/25 4:30:00 PM ET
      $CON
      Medical Specialities
      Health Care